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Abstract Abnormal Wnt signaling and impaired cell–cell
adhesion due to abnormal E-cadherin and -catenin function
have been implicated in many cancers, but have not been fully
explored in laryngeal squamous cell carcinoma. In this study,
-catenin cellular location and E-cadherin expression levels
were analyzed in 16 laryngeal squamous cell carcinomas
(LSCCs) (9 glottic and 7 supraglottic) and 11 samples of non-
tumoral inXammatory larynx tissue, using immunohistochem-
ical methods. All non-tumoral tissues showed equally strong
membranous expression of -catenin, while cytoplasmic
expression was found in only 3 of the 11 samples. By con-
trast, whereas 8/9 glottic LSCCs exhibited only membranous
expression of -catenin, 6/7 supraglottic LSCCs displayed
both membranous and cytoplasmic expression (p = 0.003).
Strong E-cadherin staining was observed in 9/11 non-tumoral
tissues and 7/9 glottic LSCCs, whereas 4/7 supraglottic
LSCCs exhibited weak expression. Reduced membrane
expression of E-cadherin and cytoplasmic retention of
-catenin in supraglottic LSCC seems to be related with
more aggressive biological behavior which has been
described in clinical studies. Further research is required to
clarify the involvement of -catenin in the mechanism
associated with malignant transformation in laryngeal tissues.
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Introduction
Laryngeal squamous cell carcinoma (LSCC), one of the
most common tumors of the head and neck, occurs mainly
in adult males who abuse tobacco and alcohol, and is char-
acterized by squamous diVerentiation. Although early-stage
glottic cancer has a favorable prognosis, with 5-year sur-
vival rates of over 70% [1], many supraglottic and subglot-
tic cancers are not diagnosed until severe signs develop, by
which time the 5-year survival rate has dropped to less than
50%. Locoregional recurrence, cervical lymph node metas-
tases and distant metastases are the factors signiWcantly
aVecting prognosis in LSCC patients [2]. The recognition
and identiWcation of tumor markers associated with recur-
rence and/or metastasis are key elements in predicting the
biological behavior of the tumor and deciding on the most
appropriate therapeutic strategy.
-Catenin, originally identiWed on the basis of its asso-
ciation with cadherin adhesion molecules, is now widely
recognized as an essential element in the wingless-Wnt
signaling cascade [3]. Wnt proteins bind to receptors
belonging to the Frizzled (Fz) family. In the canonical
pathway, -catenin activates an intracellular cascade that
involves the inhibition of glycogen synthase kinase 3
(GSK 3) and the adenomatous polyposis coli (APC) pro-
tein, ultimately resulting in the abnormal stabilization of
cytoplasmic -catenin and its translocation to the nucleus.
Nuclear -catenin then interacts with various transcription
factors to cause cellular proliferation and diVerentiation.
Abnormal Wnt signaling has been implicated in a number
of cancers including head and neck carcinoma, lung cancer,
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1184 Eur Arch Otorhinolaryngol (2012) 269:1183–1188colorectal cancer, melanoma, and leukemia [4]. Although
the role of the Wnt pathway in nasopharyngeal cancer has
not been fully explored, there is abundant evidence
that aberrant Wnt signaling is involved in its development
[5–7].
Cytoplasmic -catenin plays a major role in the normal
cell by binding to the intracellular domain of E-cadherin to
maintain cell–cell adhesion. The expression of E-cadherin
has been found to be downregulated in many cancers [8–12]
including nasopharyngeal carcinoma [5, 12]. It has been
suggested that E-cadherin downregulation may play a role
in tumor progression and metastasis.
Strong -catenin expression is signiWcantly associated
with invasion and metastasis of carcinomas of the head and
neck, esophagus, stomach, colon, liver, lung, breast, female
genitalia, prostate, bladder, and pancreas, as well as mela-
nomas [11, 14–18]. Recently, several studies have pointed
the considerable involvement of -catenin not only in
malignant transformation but also in the regulation of phys-
iological functions, and expression of this adhesion mole-
cule in human nasopharyngeal carcinoma has been
investigated [19, 20]; however, it has not yet been thor-
oughly explored in LSCC.
The present study sought to examine the possible role of
molecular cell–cell adhesion mechanisms in the oncogenesis
and/or cytodiVerentiation of laryngeal squamous cell carci-
noma. Expression of -catenin and E-cadherin was determined
in paraYn-embedded LSCC tissues and in non-tumoral tissues
from patients with inXammatory diseases of the larynx.
Materials and methods
Patient samples and histological classiWcation
Sixteen patients with well-diVerentiated LSCCs (12 men
and 4 women, aged 46–72) were diagnosed at the Infanta
Luisa Hospital in Seville (Spain). The study was approved
by the Ethical Committee and informed consent was
obtained from all the participants. LSCC samples and non-
tumoral inXammatory tissue samples (control group: six
male and Wve female patients aged 19–97) were routinely
Wxed in 10% buVered formalin and embedded in paraYn.
Histological evaluation was performed by two pathologists
using hematoxylin/eosin staining.
All patients presented with non-metastatic disease at
tumor diagnosis and survived disease-free for at least
5 years.
Immunohistochemical staining
ParaYn-embedded tissue blocks from 16 LSCC patients
and 11 patients with non-tumoral inXammation were cut
into 3 m sections and placed on APES pre-coated slides.
Sections were deparaYnized in xylene and rehydrated in
alcohol and water. Immunohistochemistry (IHC) was
performed using the peroxidase-antiperoxidase technique
after microwave antigen retrieval procedure. Antibodies for
-catenin and E-cadherin were purchased from ZYMED
Laboratories (ZYMED Laboratories, San Francisco, CA,
USA). Antibodies against -catenin (1:200) and E-cadherin
(1:100) were overlaid on NPC tissue array sections and
incubated overnight at 4°C. Secondary antibody incubation
was performed at room temperature for 30 min. Two
pathologists independently scored the results of immuno-
histochemical staining, and any discrepant scores were
reexamined to arrive at a consensus score.
For -catenin, +++ indicates positive staining in mem-
brane, cytoplasm and nucleus; positive staining in mem-
brane and cytoplasm (++); positive staining in membrane
(+). For E-cadherin, + indicates 0–50% staining cells, i.e.,
low staining: ++ 50–100% staining cells, i.e., strong or high
staining. Desmoid tumor tissues were used as positive
Table 1 Clinical data and diagnosis
F female, M male, NT Non-tumoral
Age (years) Sex (F/M) Diagnostic (localization)
1 19 M NT inXammation of larynx
2 33 F NT inXammation of larynx
3 54 M NT inXammation of larynx
4 67 M NT inXammation of larynx
5 50 F NT inXammation of larynx
6 58 M NT inXammation of larynx
7 35 F NT inXammation of larynx
8 56 M NT inXammation of larynx
9 44 F NT inXammation of larynx
10 33 F NT inXammation of larynx
11 34 M NT inXammation of larynx
12 55 F Glottic LSCC
13 54 M Supraglottic LSCC
14 49 M Supraglottic LSCC
15 48 M Glottic LSCC
16 64 M Glottic LSCC
17 48 M Supraglottic LSCC
18 51 M Glottic LSCC
19 57 F Glottic LSCC
20 50 F Supraglottic LSCC
21 61 M Glottic LSCC
22 57 M Supraglottic LSCC
23 60 F Glottic LSCC
24 62 M Glottic LSCC
25 71 M Glottic LSCC
26 63 M Supraglottic LSCC
27 72 M Supraglottic LSCC123
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primary antibodies with PBS.
Statistical analysis
Statistical analysis was performed using the SPSS for
Windows software package, release 15.0 (SPSS Inc.,
Chicago, IL, USA). Associations between antigen immuno-
reactivity, histopathological Wndings and clinical data were
evaluated by the Chi-square test. DiVerences were regarded
as signiWcant if p < 0.05.
Results
Clinical data
Patient clinical data and underlying pathologies are summa-
rized in Table 1. No correlation was found between clinical
data (age, sex, location) or mitotic numbers.
Immunohistochemical analysis
Protein expression was analyzed by immunohisto-
chemical staining for anti--catenin and anti-E-cadherin
antibodies in LSCCs and non-tumoral tissues. The 11
non-tumoral tissues showed equally strong membranous
expression of -catenin, which was detected in both
cytoplasm and membrane in only 23% of cases (3/11).
In contrast, 8/9 (89%) glottic LSCCs exhibited only
membranous expression of -catenin, whereas 6/7
(86%) supraglottic LSCCs displayed both membra-
nous and cytoplasmic expression (p = 0.003; Table 2;
Fig. 1).
Strong E-cadherin staining was observed in 9/11 (82%)
of non-tumoral tissues, and weak expression in 2/11 (18%).
Strong expression was observed in 10/16 (62%) LSCC
tissues (Fig. 2; Table 3), including 7/9 (77%) glottic
LSCCs, whereas in 4/7 (57%) supraglottic LSCCs, expres-
sion was weak (Table 3); however no signiWcant associa-
tion was found (Fig. 2).
Table 2 -Catenin: cellular localization
a The values are no. (%)
No. of cases Nucleusa Cytoplasm 
and membranea
Membranea P value 
(Chi-square test)
Non-tumoral tissues of larynx 11 0 3 (27%) 8 (73%) 0.384
LSCC tissues 16 0 7 (44%) 9 (56%)
Glottic 9 0 1 (11%) 8 (89%) 0.003
Supraglottic 7 0 6 (86%) 1 (14%)
Fig. 1 Immunohistochemical 
staining for -catenin expres-
sion. Membranous expression of 
-catenin. a Non tumoral tissue 
(£40). b Glottic laryngeal squa-
mous cell carcinoma (£40). 
Membranous and cytoplasmic 
expression of -catenin. 
c Supraglottic laryngeal squa-
mous cell carcinoma (£40). 
d Desmoid tumor (positive con-
trol for nuclear -catenin) (£40)123
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-Catenin contributes both to cell–cell adhesion and to the
Wnt signaling pathway [21, 22]. The present study noted no
alteration in -catenin protein expression between LSCCs
and non-tumoral tissues. However, diVerences were found
in the cellular location of -catenin expression: in 89% of
glottic LSCCs, -catenin was expressed only in the cell
membrane, a percentage similar to that found for non-
tumoral larynx tissue (73%), whereas in 86% of supraglot-
tic LSCCs, -catenin was expressed both in membrane and
in cytoplasm. Similar Wndings have recently been reported
by Goiliomus et al. [25] in a series of 97 LSCCs comprising
63 glottic and 34 supraglottic carcinomas. The cadherin–
catenin complex is a group of membrane proteins that are
important in cell–cell adhesion, tumor suppression, cell
diVerentiation and cell migration. Some reports have sug-
gested that downregulated expression of -catenin might
play a role in early and late tumor invasion and metastasis
[23, 24]. Downregulation of -catenin has been found to be
closely related to advanced clinical disease and short
survival in other head and neck carcinomas, including
nasopharyngeral carcinoma [12]. These results suggest that
-catenin may in itself be a major factor for supraglottic
LSCC tumor cell invasion and metastasis, and that diVer-
ences in -catenin expression between glottic and supra-
glottic carcinomas may be linked to diVerences in clinical
behavior. Here, -catenin protein levels were evaluated
using inmunohistochemical staining, a semi-quantitative
technique enabling assessment of proteins in paraYn-
embedded tissues. Further research will evaluate -catenin
expression levels using the Western blot technique, with a
view to measure possible alterations in -catenin protein
levels in fresh tissue.
-Catenin is also involved in the Wnt canonical path-
way as a transcriptional activator [21, 22]. The inhibition
of glycogen synthase kinase (GSK-3) and the APC
protein ultimately results in the stabilization and nuclear
translocation of cytoplastic -catenin. Finally, nuclear
-catenin interacts with various transcription factors to
cause proliferation and diVerentiation. But further
research is required into the link between altered -cate-
nin levels and the development of supraglottic LSCC.
Here, -catenin was detected in membrane and cytoplasm,
but not in the nucleus. Goiliomus et al. [25] in a study of
97 LSCCs, detected nuclear -catenin in only one sample,
perhaps due to diVerences in tissue processing or to the
immunohistochemical staining method used. In the pres-
ent study, failure to detect nuclear -catenin suggests that
the canonical Wnt pathway may be inactivated in this type
of cancer. This cannot be categorically conWrmed, since
stabilized -catenin was detected in cytoplasm. Further
research is required to determine the possible role of cyto-
plasmic -catenin retention in the pathogenesis of LSCC
supreglottic and whether the Wnt pathway is activated by
these retention, overexpression of its receptors or silenc-
Fig. 2 Immunohistochemical staining for E-cadherin expression. Strong staining: a (£40) Non tumoral tissue. b (£40) Glottic laryngeal squa-
mous cell carcinoma. Low staining: c (£40) Supraglottic laryngeal squamous cell carcinoma
Table 3 E-Cadherin expression
a The values are no. (%)






Non-tumoral tissues of larynx 11 2 (18%) 9 (82%) 0.250
LSCC tissues 16 6 (37.5%) 10 (62.5%)
Glottic 9 2 (22%) 7 (78%) 0.152
Supraglottic 7 4 (57%) 3 (43%)123
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activation of the non-canonical Wnt pathway that includes
signaling through calcium Xux, JNK and heterotrimeric
G proteins.
Although none of the LSCC samples expressed Wnt
pathway activators such as Wnt-1 and Wnt-5a, strong
expression of the inhibitors WIF-1 and Dkk-1 was found in
all cases. This would suggest that the Wnt pathway is inac-
tive in this type of tumor. These results enable a prelimi-
nary approach to the study of the Wnt pathway in LSCC;
future research will analyze the expression of diVerent
components of the Wnt pathway using quantitative tech-
niques (Western-blot and real-time PCR), thus overcoming
the limitations of immunohistochemical analysis and pro-
viding a more accurate view of the activation or inactiva-
tion of this signaling pathway.
E-Cadherin is essential for normal cell function, and is
downregulated in processes such as wound healing, allow-
ing epithelial cells to move and cover denuded tissue [26].
E-Cadherin, localized to the zonula adherens, complexes with
catenins  and ; - and -catenins in turn bind to -catenin
which attaches to actin Wlaments in the cell cytoskeleton
[27]. E-Cadherin is thought to act as a tumor suppressor,
since it suppresses invasion and metastasis [28]. Low
expression of E-cadherin has been shown to predict poor
outcome in oral cavity and laryngeal carcinomas [29, 30].
In the present study, strong E-cadherin expression was
detected in 82% of non-tumoral tissues and only in 62.5%
of glottic and supraglottic LSCCs. In contrast, weak E-cad-
herin expression was detected in 57% of supraglottic LSCC
tissues, while only 22% of glottic LSCCs exhibited weak
expression; the remaining 78% displayed strong E-cadherin
expression, a percentage similar to that found in non-
tumoral tissues. Downregulation of E-cadherin expression
in supraglottic LSCC tissues may indicate a greater capac-
ity for invasion and metastasis, and thus account for the
distinct clinical behavior of these tumors. Indeed, a positive
correlation was observed between E-cadherin expression
levels and the presence of lymph node metastasis in supra-
glottic LSCC tissues [31, 32]. In this respect, several
studies have shown that diminished E-cadherin expression
is a good predictor of concurrent lymph node metastasis in
laryngeal carcinoma and head and neck squamous cell
cancer [13, 33–36]. Kurtz et al. [13] noted a correlation
between reduced E-cadherin expression and decreased sur-
vival rates and vascular invasion in LSCC patients. These
Wndings may be due to mutations of the E-CADHERIN
gene [37] or to loss of heterozygosity of that gene [7]. In
some cancer cells, aberrant gene promoter methylation of
E-cadherin may be responsible for the decreased expression
of E-cadherin [33, 34]; future research will investigate
E-cadherin expression using quantitative RT-PCR, in order
to obtain a clearer view of potential diVerences between
sites, and thus focus on possible epigenetic changes due to
promoter hypermethylation in LSCC tissues.
Finally, no association was observed between E-cadherin
protein levels and -catenin localization, although low
E-cadherin levels were more common among LSCCs
exhibiting cytoplasmic -catenin (40 vs. 23.5%). Si et al.
[5] observed a signiWcant relationship between abnormal
E-cadherin and -catenin expression and clinical stage and
lymph-node metastasis, although they do not distinguish
between glottic and supraglottic LSCCs. Other studies of
head and neck squamous cell carcinomas report loss of
membranous E-cadherin and -catenin expression and
increased cytoplasmic expression, irrespective of the pri-
mary carcinoma or nodal carcinoma involved [38]. Impair-
ment of cell–cell adhesion is an essential step in the
progression from localized malignancy to stromal and vas-
cular invasion and metastatic disease. This impairment is
achieved through a variety of mechanisms involving the
cadherin/catenin complex [39].
The results obtained here suggest an enhancement of the
potential ability of cancer cells to disperse, a preliminary
step in local invasion. A better knowledge of the regulation
of the cadherin–catenin system is required for the preven-
tion or treatment of laryngeal carcinoma.
In conclusion, reduced membrane expression of E-cadherin
and cytoplasmic retention of -catenin in supraglottic
LSCC seems to be related with more aggressive biological
behavior which has been described in clinical studies.
Further research is required to clarify the involvement of
-catenin in the mechanism associated with malignant
transformation in laryngeal tissues.
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